Reckitt Benkiser completes agreement with Bristol-Myers Squibb
Reckitt Benkiser has completed its agreement with Bristol-Myers Squibb Company (BMS), having received the necessary approvals.
Reckitt Benkiser has completed its agreement with Bristol-Myers Squibb Company (BMS), having received the necessary approvals.
As reported back in February, Reckitt signed a three-year collaboration agreement under which it will license a number of Latin American consumer health care brands from BMS.
According to the terms of the agreement, Reckitt will initially pay BMS $482m to enter into the arrangement which also includes personnel, supply contracts and an option to acquire legal title to the related intellectual property at the end of the collaboration period, based on business performance.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company will have the option to purchase at the end of the three year period.
NR
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Cash in on the growth prospects of Europe's companies
Opinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
By Marcel Stotzel Published
-
Is the AI boom another dotcom bubble?
25 years on from the dotcom bubble bursting, is it time for investors to consider the sustainability of the AI boom in the stock market?
By Dan McEvoy Published